Primary Cardiac Involvement in Scleroderma and Role of Cardiac MRI

Kashif Hussain, Robert C. Stansbury

Section of Pulmonary and Critical Care Medicine, West Virginia University School of Medicine, Morgantown, USA.

DOI: 10.4236/ijcm.2014.520168                

Abstract

Systemic sclerosis (scleroderma) is a connective tissue disease characterized by vascular dysfunction and fibrosis that can affect multiple organ systems. We present case of primary cardiac involvement and the diagnostic role of cardiac MRI. Cardiovascular magnetic resonance imaging (MRI) is an accurate, quantitative method for the non-invasive assessment of myocardial perfusion. The presence of clinically apparent myocardial involvement in scleroderma portends a very poor prognosis. One study of US veterans found that clinical cardiac disease in scleroderma was associated with a 70% mortality rate at five years. Management of heart failure and conduction system abnormalities in scleroderma is similar to other cardiac disease. It includes afterload reduction, beta-blockade, defibrillator placement, etc. Patients with reduced cardiac function and normal coronary arteries may benefit from increased immune suppresion.

Keywords

Scleroderma, Primary Cardiac Involvement, Cardiac MRI

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Nagel, E., et al. (2003) Magnetic Resonance Perfusion Measurements for the Noninvasive Detection of Coronary Artery Disease. Circulation, 108, 432-437. http://dx.doi.org/10.1161/01.CIR.0000080915.35024.A9
[2]	Kahan, A. and Allanore, Y. (2006) Primary Myocardial Involvement in Systenmic Sclerosis. Rheumatology, 45, iv14-iv17. http://dx.doi.org/10.1093/rheumatology/kel312
[3]	Champion, H.C. (2008) The Heart in Scleroderma. Rheumatic Diseases Clinics of North America, 34, 181-190. http://dx.doi.org/10.1016/j.rdc.2007.12.002
[4]	Medsger, T.J. and Masi, A. (1973) Survival with Scleroderma. II. A Life-Table Analysis of Clinical and Demographic Factors in 358 Male US Veteran Patients. Journal of Chronic Diseases, 26, 647-660. http://dx.doi.org/10.1016/0021-9681(73)90054-4